This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Royal DSM And JLL Create Leading Pharma Services Company In USD 2.6 Bn Transaction; Global CDMO Company Combines DSM Pharmaceutical Products And Patheon

HEERLEN, Netherlands, Nov. 19, 2013 (GLOBE NEWSWIRE) --
JLL Partners ("JLL"), a leading middle-market private equity firm, and Royal
DSM, the global Life Sciences and Materials Sciences company, today announced
the creation of a new company, which will be a leading global contract
development and manufacturing organization (CDMO) for the pharmaceutical
industry with anticipated sales of around USD 2 billion. It will be 51% owned by
JLL and 49% by DSM.

The name of the company (provisionally called NewCo) will be announced in the
coming months. NewCo will be formed by combining DSM's business group DSM
Pharmaceutical Products ("DPP") with Patheon Inc. (TSX: PTI) ("Patheon"), after
a successful completion of the transaction described below. NewCo will be a
leading global contract development and manufacturing organization with
anticipated 2014 sales of about USD 2 billion (pro-forma) and a strong EBITDA
and operational cash flow.

NewCo will have an end-to-end offering from finished dosage (drug products) to
active substances (APIs) and a global footprint of 23 locations across North
America, Europe, Latin America and Australia with about 8,300 employees.

Combining DPP and Patheon is fully in line with DSM's strategy for its Pharma
cluster as well as an excellent value creation opportunity as DSM and JLL will
work together to maximize the value of NewCo. For DSM, combining DPP with
Patheon into NewCo is also a key step in the strategic transformation of its
Pharma activities into partnerships.

Once the transaction is complete, NewCo will add scale and new value chain
capabilities/technologies to expand its end-to-end service offering as a
comprehensive solution provider to the industry. NewCo will operate as an
independent standalone company.

The highlights of the transaction are as follows:

  * NewCo will be owned by JLL (51%) and DSM (49%).
  * JLL will contribute USD 489 million in cash to NewCo and DSM will contribute
    DSM Pharmaceutical Products (DPP) and receive a seller note of USD 200
    million, thereby valuing DPP at USD 670 million.
  * NewCo has entered into a definitive agreement to effect a Plan of
    Arrangement pursuant to the Canada Business Corporations Act ("POA") with
    Patheon under which NewCo would acquire Patheon for USD 9.32 per share in
    cash resulting in a:
      * total enterprise value for Patheon of approximately USD 1.95 billion
        (about €1.45 billion)
      * 64% premium to Patheon's closing share price on 18 November, 2013
  * Patheon's Board of Directors, acting on the unanimous recommendation of a
    committee of independent directors, recommends that Patheon' shareholders
    vote in favor of the POA.
  * JLL and the executive officers and directors of Patheon, who collectively
    own approximately 66% of the outstanding shares of Patheon, have signed
    Voting Agreements in support of the POA.
  * Committed financing to be funded at closing of USD 1.65 billion has been
    secured from J.P. Morgan, UBS, Jefferies, Morgan Stanley and KeyBank.
  * Subject to customary conditions, the transaction is expected to close in H1
  * DSM will deconsolidate DPP after closing.
  * The transaction is expected to be EPS accretive for DSM from 2015 onwards.

Patheon is a leading provider of contract development and commercial
manufacturing services to the global pharmaceutical industry, with a focus on
drug products. In the 12 months ending 31 July 2013, the company recorded
revenues of USD 943 million and pro-forma consolidated EBITDA (per credit
agreement definition) of USD 188 million. The company has around 5,900

DPP is a leading provider of contract development and manufacturing services to
the pharmaceutical, biopharmaceutical and agrochemical industries with a focus
on drug products and APIs. In 2012 DPP realized net sales of €543 million with
around 2,400 employees.

NewCo will have a unique breadth of service offerings with a focus on drug
products and APIs with a wide range of technologies and will be able to offer
comprehensive end-to-end solutions to a broad spectrum of companies ranging from
large pharmaceutical and biotech companies to specialty pharma companies,
generics and emerging pharma companies.

The combined company will also be a leader in proprietary softgel formulations
for over-the-counter, prescription and nutritional consumer products. The
exclusive synthesis products and intermediates are targeted to the crop
protection, personal care, and fine chemicals products industries.

Jim Mullen, currently CEO of Patheon, will be appointed CEO of NewCo upon
completion of the transaction. Mr. Mullen joined Patheon in 2011 as Chief
Executive Officer. Prior to joining Patheon, he served as CEO and President at
Biogen Idec Inc., one of the world's largest biotechnology companies from 2003
to 2010. He possesses over 30 years of industry experience, ranging from
biotechnology and pharmaceuticals to specialty chemicals, as well as extensive
expertise in pharmaceutical and biotech manufacturing, engineering, sales,
marketing, mergers and acquisitions.

Feike Sijbesma, CEO and Chairman of the DSM Managing Board, said: "Fully in line
with our strategy, this is for DSM Pharmaceutical Products the perfect way to
accelerate growth and for DSM to maximize value for this business. By creating a
global top CDMO organization I am convinced that NewCo as a standalone company
will be able to create substantial value. With this partnership DSM has made a
key step in the strategic transformation of its Pharma activities into
partnerships whilst creating maximal value for all stakeholders."

Paul S. Levy, Managing Director of JLL Partners, Chairman of the Board of
Patheon shared: "This partnership demonstrates JLL's commitment to building
companies that create value, fill unmet needs and drive excellence within their
respective industries. This is the strategic initiative and execution 'know how'
that stakeholders have come to expect from JLL. NewCo is poised to transform the
CDMO industry and we are excited to bring these two entities together."

Stefan Doboczky, Member of the DSM Managing Board and responsible for the Pharma
cluster,  commented: "Our customers bring life-saving and life-enhancing
medicines to people who need them around the world. They will greatly benefit
from NewCo's unmatched depth and breadth of capabilities and services. I am
convinced that NewCo will be even better positioned to help customers succeed
with their unique needs."

Financial information
DSM expects the transaction to be accretive to its earnings per share from 2015
onwards. In accordance with the applicable accounting standards DPP will be
classified as assets held for sale in Q4 2013 and a non-cash impairment loss of
around €120 million will be recognized as an exceptional item. From the closing
date onwards DSM will present the investment in NewCo as an associated account
in accordance  with the equity method. Under IFRS rules also DSM Sinochem
Pharmaceuticals will be deconsolidated from 1 January 2014. Consequently, the
reporting of the Pharma cluster in the core EBITDA of DSM will be discontinued
from the beginning of 2014.

Additional information
J.P. Morgan Limited is serving as financial advisor to DSM. Latham & Watkins LLP
is serving as lead legal advisor to DSM, supported by Cleary Gottlieb Steen &
Hamilton LLP, Norton Rose Fulbright Canada LLP, Allen & Overy and Hinckley,
Allen & Snyder LLP. Morgan Stanley and Jefferies are serving as financial
advisors to JLL Partners. Legal advisors to JLL Partners are Skadden, Arps,
Slate, Meagher & Flom LLP, Borden Ladner Gervais LLP and Simpson Thacher &
Bartlett LLP.

Conference calls
Today DSM will hold a conference call for the media from 08.00 AM - 08.30 AM CET
(+31 (0)20 53 15 871 or +44 (0) 203 365 3207) and a conference call for
investors and analysts from 09.00 AM - 10.00 AM CET (+31 (0)20 53 15 871 or +44
(0) 203 365 3207). Also, more information can be found in the presentation that
can be found on

JLL Partners
JLL Partners is a middle-market private equity firm with a 25 year track-record
of adding value to complex investments through financial and operational
expertise. Since its founding in 1988 by Paul S. Levy, JLL Partners has
committed approximately USD 4.2 billion across six funds, and developed
significant expertise in the healthcare and other sectors. JLL is a control
investor and sources its deals from its deep network of industry contacts,
applying its proven, value-oriented and growth driven investment approach to
provide limited partners with attractive risk-adjusted returns throughout all
investment cycles.

Patheon Inc. (TSX: PTI) is a leading provider of contract development and
commercial manufacturing services to the global pharmaceutical industry for a
full array of solid and sterile dosage forms. Through the company's recent
acquisition of Banner Pharmacaps - a market leader in soft gelatin capsule
technology - Patheon now also includes a proprietary products and technology
business. Patheon provides the highest quality products and services to
approximately 300 of the world's leading pharmaceutical and biotechnology
companies. The company's integrated network consists of 13 locations, including
 commercial contract manufacturing facilities and development centers across
North America and Europe. Patheon enables customer products to be launched with
confidence anywhere in the world. For more information

Patheon plans to file with the U.S. Securities and Exchange Commission (the
"SEC") and furnish to its shareholders a proxy statement and management
information circular in connection with the proposed transaction with NewCo. The
proxy statement and management information circular will also be filed on SEDAR.
PATHEON, NEWCO AND THE PROPOSED TRANSACTION. The proxy statement and management
information circular and other relevant materials (when they become available),
and any and all other documents filed by Patheon with the U.S. or Canadian
securities regulators, may be obtained free of charge at the SEC's website at or in Canada at In addition, investors and
securityholders may obtain free copies of the documents Patheon files with the
SEC or with Canadian securities regulators by directing a written request to
Patheon Inc., 2100 Syntex Court, Missisauga, Ontario, Canada L5N 7K9, Attention:
Corporate Secretary. Copies of Patheon's filings with the SEC and with Canadian
securities regulators may also be obtained at the "Investors Relations" section
of Patheon's website at

DSM - Bright Science. Brighter Living.(TM)
Royal DSM is a global science-based company active in health, nutrition and
materials. By connecting its unique competences in Life Sciences and Materials
Sciences DSM is driving economic prosperity, environmental progress and social
advances to create sustainable value for all stakeholders. DSM delivers
innovative solutions that nourish, protect and improve performance in global
markets such as food and dietary supplements, personal care, feed,
pharmaceuticals, medical devices, automotive, paints, electrical and
electronics, life protection, alternative energy and bio-based materials. DSM's
23,500 employees deliver annual net sales of around €9 billion. The company is
listed on NYSE Euronext. More information can be found

Or find us on:

For more information:
  DSM Corporate Communications        DSM Investor Relations
  Herman Betten                       Dave Huizing
  tel. +31 (0) 45 578 2421            tel. +31 (0) 45 5782864
  e-mail      e-mail

  JLL Partners                        Patheon Inc.
  Dan Agroskin                        tel. +1 919 226 3200
  tel. +1 212 210 9369                e-mail

DSM Forward-looking statements
This press release may contain forward-looking statements with respect to DSM's
future (financial) performance and position. Such statements are based on
current expectations, estimates and projections of DSM and information currently
available to the company. DSM cautions readers that such statements involve
certain risks and uncertainties that are difficult to predict and therefore it
should be understood that many factors can cause actual performance and position
to differ materially from these statements. DSM has no obligation to update the
statements contained in this press release, unless required by law. The English
language version of the press release is leading.

Patheon Forward-looking statements:
This  press release  contains "forward  looking information" or "forward-looking
statements"  within the meaning of applicableCanadian securities laws, including
statements  regarding the  proposed transaction,  the combined  company's plans,
objectives,  expectations and intentions, leadership in the contract development
and manufacturing services industry, the expected sales of the combined company,
expected  timing and benefits of the  transaction, and the preparation, delivery
and  availability of a  proxy statement and  management information circular and
other  relevant materials in  connection with the  proposed transaction, , which
forward-looking  statements may  use forward-looking  terminology such as "may",
"will",  "expect",  "anticipate",  "believe",  "continue",  "potential",  or the
negative  thereof or  other variations  thereof or  comparable terminology. Such
forward-looking statements may include, without limitation, statements regarding
the  completion of  the proposed  transaction and  other statements that are not
historical facts.

These forward-looking statements reflect beliefs and assumptions which are based
on Patheon's and Newco's perception of historical trends, current conditions and
expected  future developments, as well as  other factors management believes are
appropriate  in the circumstances. In making these statements, Patheon and Newco
have   made   assumptions  with  respect  to:  the  proposed  financing  of  the
transaction;  the ability of Patheon and Newco to achieve expected synergies and
the  timing of same;  the ability of  Patheon and Newco  to predict and adapt to
changing  customer requirements, preferences and  spending patterns; the ability
of  Patheon and  Newco to  protect their  intellectual property;  future capital
expenditures,  including the amount and  nature thereof; trends and developments
in  the  contract  development  and  manufacturing  services  industry and other
sectors of the economy which are related to these sectors; business strategy and
outlook;  expansion  and  growth  of  business  and  operations;  credit  risks;
anticipated  acquisitions; future  results being  similar to historical results;
expectations related to future general economic and market conditions; and other
matters. Patheon's and Newco's beliefs and assumptions are inherently subject to
significant   business,   economic,  competitive  and  other  uncertainties  and
contingencies  regarding  future  events  and  as  such,  are subject to change.
Patheon's  beliefs and assumptions  may prove to  be inaccurate and consequently
Patheon's  actual results could differ materially  from the expectations set out

While  such forward-looking  statements are  expressed by  Patheon, as stated in
this  release, in good faith and believed by Patheon to have a reasonable basis,
they  are  subject  to  important  risks  and  uncertainties  including, without
limitation,  the  possibility  that  certain  assumptions  with  respect  to the
proposed  transaction  could  prove  to  be  inaccurate, risks and uncertainties
relating to the transaction and financing thereof, Newco's significant levels of
indebtedness  as  a  result  of  the  proposed transaction, Newco's inability to
complete  the  anticipated  financing  as  contemplated by applicable commitment
letters  prior to  the contractually  required time  for closing of the proposed
transaction or otherwise secure favourable terms for such financing, approval of
applicable  governmental authorities, required  Patheon shareholder approval and
necessary   court  approvals,  the  satisfaction  or  waiver  of  certain  other
conditions contemplated by the Arrangement Agreement, disruptions resulting from
the   proposed  transaction  making  it  more  difficult  to  maintain  business
relationships,  and changes in applicable laws or regulations, which could cause
actual  results to differ materially from future results expressed, projected or
implied  by  the  forward-looking  statements.  As  a  result of these risks and
uncertainties,  the proposed transaction could  be modified, restructured or may
not  be completed, and the results  or events predicted in these forward-looking
statements  may differ materially from actual  results or events. These forward-
looking  statements are  not guarantees  of future  performance, given that they
involve  risks  and  uncertainties.  Patheon  is  not  affirming or adopting any
statements  made by any other person in  respect of the proposed transaction and
expressly disclaims any intention or obligation to update or revise any forward-
looking  statements, whether  as a  result of  new information, future events or
otherwise, except in accordance with applicable securities laws or to comment on
expectations  of,  or  statements  made  by  any  other person in respect of the
proposed transaction.

Investors  should not  assume that  any lack  of update  to a  previously issued
forward-looking   statement  constitutes  a  reaffirmation  of  that  statement.
Reliance on forward-looking statements is at an investors' own risk.

Cautionary Statement
No  stock  exchange,  securities  commission  or  other regulatory authority has
approved or disapproved the information contained herein.

Press release-pdf:
Presentation to investors:


Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,834.04 +21.85 0.12%
S&P 500 2,089.78 +0.64 0.03%
NASDAQ 5,111.7290 +8.9210 0.17%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs